Venture capitalist William Doyle has raised $ 35 million portfolio of companies with promising new cancer therapy, as well as global capital markets explode in fall 2008. NovoCure, Ltd, has developed an electric-field therapy, called a tumor treatment fields for the treatment of cancer. Therapy showed significant efficacy without the side effects after five years of testing in human patients. Doyle said, NovoCure has the potential to become an important business platform with major new cancer therapy, but must complete the basic (Phase III) clinical trials and approved FDA. Doyle venture capital firm WFD Ventures, invested $ 25 million in three rounds to fund pilot clinical trials for glioblastoma and other non-small cell lung cancer, and the first key clinical trials for glioblastoma. Additional funding is needed to start the second strategic basic research. In autumn 2008, Doyle was negotiating the final terms of two well-known investment hedge funds, with a liquidity crisis caused a hedge fund out of the deal. Dole must now reconsider its ability to provide the necessary funding for this promising young company. "Hide
by William A. Sahlman, Sarah Greene Flaherty Source: Harvard Business School 31 pages. Publication Date: November 24, 2009. Prod. #: 810045-PDF-ENG
Related Case Solutions & Analyses:
Marc Abrahams: Annals of an Improbable Entrepreneur
Phone Hacking and Rupert Murdoch’s News Corporation
Think You Have Power? Check Your Perceptions
Scandal at Societe Generale: Rogue Trader or Willing Accomplice?
The Science Behind Flow at Work
Measuring the Results of the HR Function: The Case of the Société de transport de Montréal’s Staffing and Workforce Planning Division
Sarah Vickers: Post Acquisition Career Management
Hr Consultancy In The Mena Region
A Simple Exercise in Accrual Accounting to Illustrate the Timing of Revenue and Expense Recognition
Duetto: Industry Transformation with Big Data
